Adenosine deaminase: Functional implications and different classes of inhibitors

Medicinal Research Reviews

Volumn 21, Issue 2, 2001, Pages 105-128

  Cristalli, Gloria ^a   Costanzi, Stefano ^a   Lambertucci, Catia ^a   Lupidi, Giulio ^a   Vittori, Sauro ^a   Volpini, Rosaria ^a   Camaioni, Emidio ^b  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Adenosine deaminase; Adenosine deaminase deficiency; Adenosine deaminase in pathology; Adenosine deaminase inhibitors; Adenosine metabolism enzymes

Indexed keywords

1 DEAZAADENOSINE; ADENOSINE DEAMINASE; ADENOSINE DEAMINASE INHIBITOR; ANTILEUKEMIC AGENT; ANTIVIRUS AGENT; COFORMYCIN; DIPYRIDAMOLE; FLAVONOID; LIDOFLAZINE; MACROGOL; NUCLEOSIDE DERIVATIVE; PENTOSTATIN; PHENYLBUTAZONE; TRAZODONE;

COMBINED IMMUNODEFICIENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME STRUCTURE; GENE THERAPY; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; ISCHEMIA; LYMPHOPROLIFERATIVE DISEASE; REVIEW;

ADENOSINE DEAMINASE; ANIMALS; ENZYME INHIBITORS; GENE THERAPY; HUMANS; ISOENZYMES; MOLECULAR STRUCTURE; SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTES;

EID: 0035120798     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-1128(200103)21:2<105::AID-MED1002>3.0.CO;2-U     Document Type: Review

References (235)

1. The deaminases of adenosine and adenylic acid in blood and tissues
2. Purification, characterization and radioimmunoassay of adenosine deaminase from human leukaemic granulocytes
3. Purification and partial characterization of brain adenosine deaminase: Inhibition by purine compounds and by drugs
4. Human adenosine deaminase. Distribution and properties
5. Increased excretion of modified adenine nucleosides by children with adenosine deaminase deficiency
6. 6-(d2-isopentenyl)adenosine: Its conversion to inosine, catalyzed by adenosine aminohydrolase from chicken bone marrow and calf intestine mucosa
7. Purine, Purine nucleoside and purine nucleoside amino hydrolases
8. An evolutionary treasure: Unification of a broad set of amidohydrolases related to urease
9. A study of the tissue distribution of adenosine deaminase in six mammal species
10. Deduced amino acid sequence of Escherichia coli adenosine deaminase reveals evolutionary conserved amino acid residues: Implication for catalytic function
11. Primary structure of bovine adenosine deaminase
12. Diverse genetic regulatory motifs required for murine adenosine deaminase gene expression in the placenta
13. The crystal structure of urease from Klebsiella aerogenes
14. Adenosine deaminase from Saccharomyces cerevisiae: Interaction with ground and transition state analogs
15. Purification and properties of the adenosine deaminase from the midgut gland of a marine bivalved mollusk Atrina spp
16. Two different hepatic adenosine deaminase in the chicken
17. A study of the tissue distribution of adenosine deaminase in six mammal species
18. Purification and characterization of calf brain adenosine deaminase
19. Adenosine deaminase from human erythrocytes: Purification and effects of adenosine analogs
20. Analysis of normal and mutants forms of human adenosine deaminase
21. Human adenosine deaminase
22. Adenosine deaminase activity in thymus and other human tissues
23. The distribution of adenosine deaminase among lymphocyte populations in the rat
24. An immunomorphological study of adenosine deaminase distribution in human thymus tissue, normal lymphocytes, and hematopoietic cell lines
25. Adenosine deaminase activity in chronic lymphocytic leukemia: Relationship to B- and T-cell subpopulation
26. Differential distribution of purine metabolizing enzymes between glia and neurons
27. Enzymes involved in purine metabolism - A review of histochemical localization and functional implications
28. Human adenosine deaminase. cDNA and complete primary amino acid sequence
29. Sequence of human adenosine deaminase cDNA including the coding region and a small intron
30. Adenosine deaminase: Characterization and expression of a gene with a remarkable promoter
31. Complete sequence and structure of the gene for human adenosine deaminase
32. Identification of functional murine adenosine deaminase cDNA clones by complementation in Escherichia coli
33. Structural and functional analysis of the murine adenosine deaminase gene
34. A 43.5 kb segment of yeast chromosome XIV, which contains MFA2, MEP2, CAP/SRV2, NAM9, FKB1/FPR1/RBP1, MOM22 and CPT1, predicts an adenosine deaminase gene and 14 new open reading frames
35. Gene organization in the ada-rp1L region of Streptomyces virginiae
36. Atomic structure of adenosine deaminase with transition-state analog: Understanding catalysis and immunodeficiency mutations
37. Refined 2.5 Å structure of murine adenosine deaminase at pH 6.0
38. A pre-transition-state of an enzyme: X-ray structure of adenosine deaminase with bound 1-deazaadenosine and zinc-activated water
39. Probing the functional role of two conserved active site aspartates in mouse adenosine deaminase
40. Site-directed mutagenesis of histidine 238 in mouse adenosine deaminase: Substitution of histidine 238 does not impede hydroxylate formation
41. Complexes of adenosine deaminase with two potent inhibitors: X-ray structures in four independent molecules at pH of maximum activity
42. Transition-state discrimination by adenosine deaminase from Aspergillus oryzae
43. Crystallization and preliminary analysis of bovine adenosine deaminase
44. Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors
45. Localization of purine metabolizing enzymes in bovine brain microvessel endothelial cells: An enzymatic blood-brain barrier for dideoxynucleosides?
46. Cell surface adenosine deaminase: Much more than an ectoenzyme
47. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes
48. Presence of adenosine deaminase on the surface of mononuclear cells: Immunochemical localization using light and electron microscopy
49. Direct association of adenosine deaminase with a T-cell activation antigen
50. Subcellar distribution of adenosine daeminase and adenosine deaminase complessing protein in rabbit kidney: Implication for adenosine metabolism
51. Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex: Possible role of adenosine deaminase as costimolatory molecule
52. Adenosine deaminase in rodent median eminence: Detection by antibody to the mouse enzyme and co-localization with adenosine deaminase-complexing protein (CD26)
53. Dipeptidyl-peptidase IV/CD26 on T cells - Analysis of an alternative T-cell activation pathway
54. Dipeptidyl-peptidase IV from human serum purification, characterization, and N-terminal amino acid sequence
55. The CP-I subunit of adenosine deaminase complexing protein from calf kidney is identical to human, mouse, and rat dipeptidyl-peptidase IV
56. Dipeptidyl-peptidase IV-β - Further characterization and comparison to Dipeptidyl-peptidase IV activity of CD26
57. Adenosine deaminase increases release of excitatory amino acids through a mechanism independent of adenosine depletion
58. 1 adenosine receptors in pig brain cortical membranes
59. How important is the N-3 sugar moiety in the tight-binding interaction of coformycin with adenosine-deaminase
60. Theoretical study of inhibition of adenosine deaminase by (8R)- coformycin and (8R)-deoxycoformycin
61. Theoretical study of the hydroxyl nucleophilic attack on the 6-aminopyrimidine molecule: Functional implications in the reaction mechanism of nucleoside deaminative enzymes
62. A quantum chemical study of the enzymatic deamination of benzoadenine derivative. A theoretical model of the interactions occurring between nucleosides and the active site of adenosine deaminase
63. Determination of the conformational preferences of adenosine at the active site of adenosine deaminase
64. Quantum chemical study of the electronic and conformational characteristics of adenosine and 8-substituted derivatives: Functional implication in the mechanism of reaction of adenosine deaminase
65. The role of divalent cations in structure and function of routine adenosine deaminase
66. On the role of tryptophan in the activity of adenosine deaminase
67. Functional residues at the active site of bovine brain adenosine deaminase
68. Photoinactivation studies on adenosine deaminase
69. Tryptophan environment in adenosine deaminase: Enzyme modification with N-bromosuccinimide in the presence of adenosine and EHNA analogs
70. Adenosine-deaminase inhibitors structure-activity relationships in 1-deazaadenosine and erythro-9-(2-hydroxy-3- nonyl)adenine analogs
71. Isoenzymes of adenosine deaminase
72. Comparison and possible omology of isozymes of adenosine deaminase in aves and humans
73. Serum adenosine deaminase in normals and in a patient with adenosine deaminase deficient-severe combined immunodeficiency
74. Serum adenosine deaminase: Isoenzymes and diagnostic application
75. Automated enzymatic measurements of adenosine deaminase isozymes activities in serum
76. 2: A marker for human immunodeficiency virus infection
77. Serum adenosine deaminase activity and its isoenzyme pattern in patients with systemic lupus erythematosus
78. 2: Diagnostic and biological role
79. A correlation study between serum adenosine deaminase activities and peripheral lymphocyte subsets in Parkinson's disease
80. 2
81. Adenosine deaminase isozymes of the opossum Didelphis virginiana: Initial chromatographic and kinetic studies
82. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity
83. Purine nucleoside metabolism in the erythrocytes of patients with adenosine deaminase deficiency and severe combined immunodeficiency
84. Purine metabolism in adenosine deaminase deficiency
85. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency
86. Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency
87. Adenosine deaminase and severe combined immunodeficiency cesease
88. Adenosine deaminase deficiency: Recent observations pertinent to investigation of the physiologic role of adenosine in man
89. Adenosine deaminase deficiency: Molecular basis and recent developments
90. In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2′-deoxyadenosine in adenosine deaminase-deficient patients
91. Metabolic and immunologic consequences of limited adenosine deaminase expression in mice
92. S-adenosylhomocysteine catabolism and basis for acquired resistence during treatment of T-cell acute lymphoblastic leukemia with 2′-deoxycoformycin alone and in combination with 9-β-D-arabinofur-anosyladenine
93. Adenosine deaminase-deficient mice die perinatally and exhibit liver-cell degeneration, atelectasis and small intestinal cell death
94. Structure of adenosine deaminase mRNAs from normal and adenosine deaminase-deficient human cell lines
95. Molecular cloning of human adenosine deaminase gene sequences
96. Isolation of cDNA clones for human adenosine deaminase
97. Cloning of cDNA sequences of human adenosine deaminase
98. Structure of adenosine deaminase mRNAs from normal and adenosine deaminase-deficient human cell lines
99. Adenosine deaminase (ADA) deficiency in cells derived from humans with severe combined immunodeficiency is clue to an aberation of the ADA protein
100. Elevated adenosine deaminase and purine nucleoside phosphorilase activity in peripheral blood null lymphocytes from patients with aquired immune deficiency syndrome
101. One adenosine deaminase allele in a patient with severe combined immunodeficiency contains a point mutation abolishing enzyme
102. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response
103. Identification of a point mutation in the adenosine deaminase gene responsible for immunodeficiency
104. Mutant human adenosine deaminase alleles and their expression by transfection into fibroblasts
105. Identification of a point mutation resulting in a heat-labile adenosine deaminase (ADA) in two unrelated children with partial ADA deficiency
106. Identification of two new missense mutations (R156C and S291L) in two ADA-SCID patients unusual for response to therapy with partial exchange transfusions
107. Novel splicing, missense, and deletion mutations in seven adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency disease. Contribution of genotype to phenotype
108. Homozygosity for a missense mutation (G20R) associated with neonatal onset adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID)
109. Three new adenosine deaminase mutations that define a splicing enhancer and cause severe and partial phenotypes: Implications for evolution of a CpG hotspot and expression of a transduced ADA cDNA
110. Four new adenosine deaminase mutations, altering a zinc-binding histidine, two conserved alanines, and a 5′ splice site
111. Adenosine deaminase deficiency: Molecular basis and recent development
112. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorilase deficiency
113. Two newly identified mutations (Thr233Ile and Leu152Met) in partially adenosine deaminase-deficient (ADA) individuals that result in differing biochemical and metabolic phenotypes
114. Clinical expression, genetics and therapy of adenosine deaminase (ADA) deficiency
115. Seven novel mutations in the adenosine deaminase (ADA) gene in patients with severe and delayed onset combined immunodeficiency: G74C, V129M, G140E, R149W, Q199P, 462delG, and E337del
116. Tissue-specific rescue suggests that placental adenosine deaminase is important for fetal development in mice
117. Modelling of purine nucleoside metabolism during mouse embryonic development. Relative routes of adenosine, deoxyadenosine and deoxyguanosine metabolism
118. An intron 1 regulatory region from the murine adenosine gene can activate heterologous promoters for ubiquitous expression in transgenic mice
119. Diverse genetic regulatory motifs required for murine adenosine deaminase gene expression in the placenta
120. Ontogeny of adenosine deaminase in the mouse decidua and placenta: Immunolocalization and embryo transfer studies
121. Coordinate developmental regulation of purine catabolic enzyme expression in gastrointestinal and postimplantation reproductive tracts
122. Adenosine levels in postimplantation mouse uterus: Quantitation by HPLC-fluorimetric detection and spatiotemporal regulation by 5′-nucleotidase and adenosine deaminase
123. Adenosine deaminase activity and acquired immunodeficiency syndrome (AIDS)
124. Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles
125. Adenosine deaminase in body fluids: A useful diagnostic tool in tuberculosis
126. Significance of adenosine deaminase activity and its isoenzymes in tuberculous effusions
127. Evaluation of adenosine deaminase activity in the Mycobacterium tuberculosis culture supernatants
128. Adenosine deaminase levels in cerebrospinal fluid of patients with confirmed tuberculosis and bacterial meningitis
129. Adenosine deaminase concentration in cerebrospinal fluid during brucella meningitis
130. Adenosine deaminase activity in the CSF of patients with aseptic meningitis: Utility in the diagnosis of tuberculous meningitis or neurobiucellosis
131. High levels of adenosine deaminase in patients with aseptic meningitis
132. Adenosine deaminase activity in sera lymphocytes and granulocytes in patients with cutaneous leishmaniasis
133. Adenosine deaminase activity in the aetiological diagnosis of community-acquired pneumonia
134. Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia
135. Adenosine deaminase activity in adult T cell leukemia
136. Adenosine deaminase activity in Lymphoid subpopolations and leukemias
137. The correlation of adenosine deaminase and purine nucleoside phosphorilase activities in human lymphocytes subpopulation and in various lymphoid malignancies
138. Comparison of purine degradative enzymes and terminal deoxynucleotidyl transferase in T-cell leukemias and in normal thymic and post-thymic T-cells
139. Genetic deficiency of adenosine deaminase and purine nucleoside phosphorilase and their implication for therapy of leukemias
140. Adenosine deaminase activity in sera of patients with psoriasis, mycosis fungoides and adult T cell leukemia
141. Purine nucleotide metabolism: Specific aspects in chronic lymphocytic leukemia lymphocytes
142. Adenosine deaminase and adenosine kinase in rat hepatomas and kidney tumours
143. Characterization of adenosine deaminase from normal colon and colon tumors. Evidence for tumor-specific variant
144. Simultaneous assay of adenosine deaminase and purine nucleoside phosphorylase activity as possible biochemical means to detect non-Hodgkin lymphomas of oral cavity
145. Distribution of adenosine deaminase binding protein in normal and malignant tissues of gastrointestinal tract studied by monoclonal antibodies
146. Adenosine deaminase activity in gastric cancer
147. Adenosine deaminase in human epidermis from healthy and psoriatic subjects
148. Characterization of adenosine deaminase from normal human epidermis and squamous cell carcinoma in the skin
149. Hereditary hemolytic anemia with increased red cell adenosine deaminase (45 to 70-fold) and decreased adenosine triphosphate
150. Elevated erythrocyte adenosine deaminase activity in congenital hypoplastic anemia
151. Serum and synovial fluid adenosine deaminase activity in patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis
152. Red blood cell adenosine deaminase activity in multiple sclerosis
153. Adenosine deaminase activity in progressive systemic sclerosis
154. High serum adenosine deaminase activity and its correlation with lymphocyte subsets in myasthenia gravis
155. A comparative study of serum deaminase in systemic rheumatic diseases
156. Elevated erythrocyte adenosine deaminase activity in Down's syndrome
157. Erythrocyte adenosine deaminase, purine nucleoside phosphorylase and phosphoribosyltransferase activity in patients with Down's syndrome
158. Adenosine deaminase activity in blood patients with stable angina pectoris
159. Changes of serum adenosine deaminase activity induced by stress in rats
160. Overview of biochemical abnormalities and molecular genetics of adenosine deaminase deficiency
161. Adenosine deaminase deficiency: Disappearance of adenine deoxynucleotides from a patient's erytrocytes after successful marrow transplantation
162. Treatment of adenosine deaminase deficiency with polyethyleneglycol-modified adenosine deaminase
163. T lymphocyte-directed gene-therapy for ADA-SCID: Initial trial results after 4 years
164. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients
165. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine-deaminase deficiency
166. Bone marrow gere transfer in three patients with adenosine deaminase deficiency
167. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency
168. Gene therapy for severe combined immunedeficiency caused by adenosine deaminase deficiency: Improved retroviral vectors for clinical trials
169. Deoxycoformycin in the treatment of leukemias and lymphomas
170. The activity of deoxycoformycin (pentostatin) in refractory leukemias and lymphomas
171. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2′-deoxycoformycin
172. Adenosine deaminase inhibitors: Their role in chemotheraphy and immunosuppression
173. Adenosine deaminase in herpes simplex virus induced corneal stromal disease
174. Enhancement of 9-β-D-arabinofuranosyladenine cytotoxicity in mouse leukemia L1210 in vitro by 2′-deoxycoformycin
175. Enhancement of the biological activity of cordycepin (3′-deoxyadenosine) by the adenosine deaminase inhibitor 2′-deoxycoformycin
176. Enhancement of the antitumor activity of arabinofuranosyladenine by 2′-deoxycoformycin
177. Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2′-deoxycoformycin
178. Potentiation by 2′-deoxycoformycin of the inhibitory effect by 3′-deoxyadenosine (cordycepin) on nuclear RNA synthesis in 11210 cells in vitro
179. Effect of the adenosine deaminase inhibitor 2′-deoxycoformycin on the repair and expression of potentially lethal damage sensitive to β-ara A
180. 6-cyclopentyladenosine and 8-cyclopentyl-1,3-dipropylxanthine on N-methyl-D-aspartate induced seizures in mice
181. Status epilepticus may be caused by loss of adenosine anticonvulsant mechanism
182. Increases in interstitial adenosine and cerebral blood flow with inhibition of adenosine kinase and adenosine deaminase
183. Involvement of adenosinedeaminase and adenosine kinase in regulating extracellular adenosine concentration in rat hippocampal slices
184. Modulation of adenosine release from rat spinal cord by adenosine deaminase and adenosine kinase inhibitors
185. Pharmacological augmentation of excitatory amino acid-evoked adenosine release from rat cortical slices
186. Potentiation of excitatory amino acid-evoked adenosine release from rat cortex by inhibitors of adenosine kinase and adenosine deaminase and by acadesine
187. Co-administration of adenosine kinase and deaminase inhibitors produces supra-additive potentiation of N-methyl-D-aspartate-evoked adenosine formation in cortex
188. Antinociceptive and anti-inflammatory properties of an adenosine kinase inhibitor and an adenosine deaminase inhibitors
189. Cardiac electrophysiological actions of adenosine
190. Harnessing an endogenous cardioprotective mechanism: Cellular sources and site of action of adenosine
191. Protective effects of an adenosine deaminase inhibitor on ischemia-reperfusion injury in isolated perfused rat heart
192. Adenosine deaminase inhibitors attenuate injury and preserve energy balance in isolated guinea pig heart
193. Effects of adenosine deaminase inhibition on blood pressure in old spontaneously hypertensive rats
194. Mode of inhibition of coformycin on adenosine deaminase
195. A novel adenosine and Ara-A deaminase inhibitor (R)-3-(2-deoxy-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro imidazo[4,5-d][1,3]diazepin-8-ol
196. Tight-binding inhibitors IV. Inhibition of adenosine deaminase by various inhibitors
197. Spontaneous epimerization of (S)-deoxycoformycin and interaction of (R)-deoxycoformycin. (S)-deoxycoformycin, and 8-ketodeoxycoformycin with adenosine deaminase
198. Total synthesis of (8R)-3-(2-deoxy-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d] [1,3]diazepin-8-ol (Pentostatin), the potent inhibitor of adenosine deaminase
199. Study on the inhibition of adenosine deaminase
200. Adenosine deaminase inhibitors. Synthesis and biological evaluation of (+/-)-3,6,7,8-tetrahydro-3-[(2-hydroxyethoxy)methyl]imidazo[4,5-d] [1,3]diazepin-8-ol and some selected C-5 homologues of pentostatin
201. Adechlorin, a new adenosine deaminase inhibitor containing chlorine, production, isolation and properties
202. The biochemical pharmacology of (2′-R)-chloropentostatin, a novel inhibitor of adenosine deaminase
203. Adecypenol, a unique adenosine deaminase inhibitor containing homopurine and cyclopentene rings. Taxonomy, production and enzyme inhibition
204. Inhibition of adenosine deaminase by deaza derivatives of adenosine and purine riboside
205. Inhibition of adenosine deaminase from several sources by deaza derivatives of adenosine and EHNA
206. Adenosine deaminase inhibitors: Synthesis and structure-activity relationships of imidazole analogues of erythro-9-(2-hydroxy-3-nonyl)adenine
207. Purine and 1-deazapurine ribonucleosides and deoxyribonucleosides: Synthesis and biological activity
208. 6-cycloalkyl derivatives of 1-deazaadenine nucleosides: A new class of anti-human immunodeficiency virus agents
209. Studies on adenosine deaminase. 1 Purification and property of ox heart adenosine deaminase
210. Synthesis and adenosine deaminase inhibitory activity of 3′-deoxy-1-deazaadenosines
211. Enzyme inhibotors. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl)adenines
212. Adenosine deaminase from human erythrocytes
213. Adenosine deaminase: Viscosity studies and mechanism of binding of substrate and of ground- and transition-state inhibitors
214. Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition
215. Enzyme inhibitors X11. Synthesis of an active-site-directed irreversible inhibitor of adenosine deaminase
216. Structure-activity relationships in adenosine deaminase inhibitors
217. Design and evaluation of enzyme inhibitors, especially of adenosine deaminase
218. Adenosine deaminase4 inhibitors. 26. Synthesis and biological evaluation of C1′ and nor-C1′ derivatives of (+)-erythro-9-(2(S)-hydroxy-3(R)-nonyl)adenineminase
219. Adenosine deaminase inhibitors. Synthesis and biological evaluation of 4-amino-1-(2(S)-hydroxy-3(R)-nonyl)-1H-imidazo[4,5-c]pyridine (3-deaza-(+)-EHNA) and certain C1′ derivatives
220. Adenosine deaminase inhibitors. Synthesis and biological evaluation of aralkyladenines (ARADS)
221. Regulation of adenosine concentration and cytoprotective effects of novel reversible adenosine deaminase inhibitors
222. Adenosine deaminase inhibitors. Synthesis and biological evaluation putative metabolite of (+)-erythro-9-(2(S)-hydroxy-3(R)-nonyl)adenine
223. Adenosine deaminase inhibitors. Syntnesis and biological evaluation of chain modified analogs of (+)-EHNA
224. Probing the active site of adenosine deaminase a pH responsive fluorescent competitive inhibitor
225. Adenosine deaminase inhibitors. Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine
226. Adenosine deaminase inhibitors. Synthesis and biological activity of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine
227. Adenosine deaminase inhibitors: Synthesis and structure-activity relationships of 2-hydroxy-3-nonyl derivatives of azoles
228. Adenosine deaminase inhibitors: Synthesis, diastereoisomeric resolution and biological activity of 1-(2-hydroxy-3-nonyl)-1,2,4-triazole-3- carboxamide
229. Garlic and onion extractes: In vitro inhibition of adenosine deaminase
230. In vitro inhibition of adenosine deaminase by a group of steroid and triterpenoid compounds
231. In vitro inhibition of adenosine deaminase by flavonoids and related compounds. New insight into the mechanism of action of plant phenolics
232. Inhibition of adenosine-deaminase activity of aortic endothelial-cells by selected flavonoids
233. Effects of dipyridamole, soluflazine and related molecules on adenosine uptake and metabolism by isolated human red blood cells
234. Trazodone, a nontricyclic antidepressant, is an inhibitor of adenosine deaminase